NCT01689155View on ClinicalTrials.gov

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

CompletedOBSERVATIONAL
Enrollment

116

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

April 30, 2016

Conditions
MeningitisMeningococcal Infection
Interventions
BIOLOGICAL

Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

Trial Locations (1)

94612

Oakland

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01689155 - Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children | Biotech Hunter | Biotech Hunter